Polyrizon (NASDAQ:PLRZ – Get Free Report) was upgraded by Wall Street Zen to a “sell” rating in a report released on Saturday.
Polyrizon Stock Performance
Shares of NASDAQ PLRZ opened at $0.97 on Friday. The company’s 50 day moving average price is $77.81. Polyrizon has a 52-week low of $0.55 and a 52-week high of $1,200.00.
Institutional Trading of Polyrizon
A hedge fund recently bought a new stake in Polyrizon stock. Citadel Advisors LLC acquired a new stake in shares of Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 38,337 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.91% of Polyrizon as of its most recent SEC filing.
Polyrizon Company Profile
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Recommended Stories
- Five stocks we like better than Polyrizon
- What Do S&P 500 Stocks Tell Investors About the Market?
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- What is Insider Trading? What You Can Learn from Insider Trading
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- Where to Find Earnings Call Transcripts
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
